NBY Valuation

NovaBay Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.130

+0.02(0.948%)1D

Overview
Forecast
Valuation
Earnings

NBY Relative Valuation

NBY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NBY is overvalued; if below, it's undervalued.

Historical Valuation

NovaBay Pharmaceuticals Inc (NBY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -2.19. The fair price of NovaBay Pharmaceuticals Inc (NBY) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.11 USD , NovaBay Pharmaceuticals Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：2.11

Fair

Undervalued

-2.45

Trailing

Forward

-2.42

EV/EBITDA

NovaBay Pharmaceuticals Inc. (NBY) has a current EV/EBITDA of -2.42. The 5-year average EV/EBITDA is -2.00. The thresholds are as follows: Strongly Undervalued below -5.45, Undervalued between -5.45 and -3.72, Fairly Valued between -0.27 and -3.72, Overvalued between -0.27 and 1.45, and Strongly Overvalued above 1.45. The current Forward EV/EBITDA of -2.42 falls within the Historic Trend Line -Fairly Valued range.

-1.58

EV/EBIT

NovaBay Pharmaceuticals Inc. (NBY) has a current EV/EBIT of -1.58. The 5-year average EV/EBIT is -1.36. The thresholds are as follows: Strongly Undervalued below -3.55, Undervalued between -3.55 and -2.46, Fairly Valued between -0.27 and -2.46, Overvalued between -0.27 and 0.82, and Strongly Overvalued above 0.82. The current Forward EV/EBIT of -1.58 falls within the Historic Trend Line -Fairly Valued range.

0.88

NovaBay Pharmaceuticals Inc. (NBY) has a current PS of 0.88. The 5-year average PS is 0.95. The thresholds are as follows: Strongly Undervalued below -1.44, Undervalued between -1.44 and -0.24, Fairly Valued between 2.14 and -0.24, Overvalued between 2.14 and 3.33, and Strongly Overvalued above 3.33. The current Forward PS of 0.88 falls within the Historic Trend Line -Fairly Valued range.

-2.59

P/OCF

NovaBay Pharmaceuticals Inc. (NBY) has a current P/OCF of -2.59. The 5-year average P/OCF is -2.21. The thresholds are as follows: Strongly Undervalued below -6.10, Undervalued between -6.10 and -4.16, Fairly Valued between -0.26 and -4.16, Overvalued between -0.26 and 1.69, and Strongly Overvalued above 1.69. The current Forward P/OCF of -2.59 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

NovaBay Pharmaceuticals Inc. (NBY) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.07. The thresholds are as follows: Strongly Undervalued below -0.41, Undervalued between -0.41 and -0.17, Fairly Valued between 0.31 and -0.17, Overvalued between 0.31 and 0.55, and Strongly Overvalued above 0.55. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

NovaBay Pharmaceuticals Inc (NBY) has a current Price-to-Book (P/B) ratio of 2.90. Compared to its 3-year average P/B ratio of -0.16 , the current P/B ratio is approximately -1930.81% higher. Relative to its 5-year average P/B ratio of 0.84, the current P/B ratio is about 246.91% higher. NovaBay Pharmaceuticals Inc (NBY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -165.82%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -114.59% , the current FCF yield is about -100.00% lower.

2.90

P/B

Median3y

-0.16

Median5y

0.84

25.39

FCF Yield

Median3y

-165.82

Median5y

-114.59

Competitors Valuation Multiple

The average P/S ratio for NBY's competitors is 34.70, providing a benchmark for relative valuation. NovaBay Pharmaceuticals Inc Corp (NBY) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NBY.A

NovaBay Pharmaceuticals Inc

Lyra Therapeutics Inc

Bio Green Med Solution Inc

Ernexa Therapeutics Inc

Bolt Biotherapeutics Inc

Performance Decomposition

Market capitalization of NBY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NBY in the past 1 year is driven by Unknown.